Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.
NextGen Healthcare (NXGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal first-quarter earnings reflect strong segmental performance.
Cerner (CERN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) second-quarter results benefit from gains across six of its business units.
Company News for Jul 28, 2021
by Zacks Equity Research
Companies In The News Are: RGEN, SIRI, BSX, FISV.
Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up
by Zacks Equity Research
Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 8.11% and 4.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Boston Scientific (BSX) Ahead of Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
by Zacks Equity Research
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni
Top Analyst Reports for Oracle, Lockheed Martin & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Lockheed Martin (LMT), and Boston Scientific (BSX).
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake
by Zacks Equity Research
Boston Scientific (BSX) currently holds an equity stake of roughly 27%.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows
by Zacks Equity Research
The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.
Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe
by Zacks Equity Research
Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).
CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.
Bruker's (BRKR) Research Tools Enable New insight on PACS
by Zacks Equity Research
Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
by Zacks Equity Research
Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
by Zacks Equity Research
Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.